N-(2-(3-Ethoxyphenoxy)ethyl)-4-Formylbenzamide is an aldehyde-functionalized ADC linker enabling selective bioorthogonal conjugation for site-specific antibody-drug conjugate synthesis and improved targeted payload delivery.
Structure of 1226006-55-8
* For research and manufacturing use only. We do not sell to patients.
Size | Price | Stock | Quantity |
---|---|---|---|
-- | $-- | In stock |
Looking for different specifications? Click to request a custom quote!
Capabilities & Facilities
N-(2-(3-Ethoxyphenoxy)ethyl)-4-Formylbenzamide is gaining notable attention within the pharmaceutical research community due to its unique molecular structure and significant potential for diverse therapeutic applications. The incorporation of ethoxyphenoxy and formylbenzamide groups into the compound’s framework allows for precise molecular interactions, making it an attractive candidate for drug development. These structural features not only confer potential biological activity but also provide the versatility needed to address various medical challenges, highlighting its role in advancing current treatment methodologies. Researchers are focused on understanding its full scope and potential across numerous disease pathways.
In the field of oncology, N-(2-(3-Ethoxyphenoxy)ethyl)-4-Formylbenzamide is being extensively studied for its potential as an anti-cancer agent. The compound is believed to interfere with key signaling pathways that regulate cell proliferation and apoptosis, thereby inhibiting tumor growth and progression. Its specificity in targeting cancer cells while sparing normal tissue presents a promising approach to cancer treatment, aiming to reduce the severe side effects associated with conventional therapies. Ongoing research aims to validate its effectiveness across different cancer types and establish it as a viable option in targeted cancer therapy.
Beyond its applications in oncology, this compound is noted for its potential anti-inflammatory properties. Chronic inflammatory diseases, such as rheumatoid arthritis and ulcerative colitis, could greatly benefit from treatments that effectively manage inflammation and provide sustained relief. N-(2-(3-Ethoxyphenoxy)ethyl)-4-Formylbenzamide is being investigated for its ability to modulate immune responses and decrease the production of pro-inflammatory cytokines. If successful, these studies could result in new therapies that not only alleviate symptoms but also impede disease progression, improving the quality of life for patients affected by chronic inflammatory disorders.
Additionally, N-(2-(3-Ethoxyphenoxy)ethyl)-4-Formylbenzamide shows exciting potential in neuroprotective applications. Neurodegenerative diseases, including Alzheimer’s and Parkinson’s disease, represent ongoing challenges in medicine due to their complex, progressive nature. This compound may provide neuroprotective effects by stabilizing neuronal cells and potentially slowing the progression of these disorders. By focusing on mechanisms that protect and maintain neuronal integrity, researchers hope to develop novel treatments that not only manage symptoms but also alter the disease course. These investigations underscore the compound’s versatility and potential to pioneer advances in therapeutic strategies for complex neurodegenerative conditions.
Catalog | Product Name | CAS | Inquiry |
---|---|---|---|
BADC-00523 | N-(2-(2-Chloroethoxy)ethyl)-4-Formylbenzamide | 1137575-49-5 | |
BADC-00531 | N-(2-(4-Fluorophenoxy)ethyl)-4-Formylbenzamide | 1225588-22-6 | |
BADC-00532 | N-(2-(3-Fluorophenoxy)ethyl)-4-Formylbenzamide | 1225588-29-3 | |
BADC-00533 | N-(2-(2-Fluorophenoxy)ethyl)-4-Formylbenzamide | 1225705-45-2 | |
BADC-00534 | N-(2-(3-Ethylphenoxy)ethyl)-4-Formylbenzamide | 1225790-49-7 | |
BADC-00535 | N-(2-(4-Ethylphenoxy)ethyl)-4-Formylbenzamide | 1225790-59-9 | |
BADC-00536 | N-(2-(2,6-Dimethylphenoxy)ethyl)-4-Formylbenzamide | 1225936-91-3 | |
BADC-00539 | N-(2-(2-Chlorophenoxy)ethyl)-4-Formylbenzamide | 1225972-65-5 | |
BADC-00540 | N-(2-((2,3-Dihydro-1H-Inden-5-yl)oxy)ethyl)-4-Formylbenzamide | 1225979-81-6 | |
BADC-00541 | N-(2-(Benzo[d][1,3]dioxol-5-yloxy)ethyl)-4-Formylbenzamide | 1226006-03-6 |
Contact our experts today for pricing and comprehensive details on our ADC offerings.
From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.
Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.
Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.